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Background: Trypanosomosis or Surra, caused by the flagellated hemoprotozoan parasite Trypanosoma evansi, is a
disease of economic importance through its wide prevalence in domestic livestock in tropical countries. In the absence
of a protective vaccine, management of the disease relies on a few available chemotherapeutic agents. Although
humoral immunity is the mainstay of resistance to T. evansi, the ability of the parasite to vary its immunodominant
surface proteins to subvert the immune system has forced vaccine efforts to target a variety of invariant epitopes. Beta
tubulin, an integral component of the trypanosome cytoskeleton, was therefore targeted using the recombinant form
of the protein for immunization.
Methods: The 1329 bp coding sequence of beta tubulin gene was PCR amplified and cloned in pQE-
TriSystem expression vector. Recombinant beta tubulin was heterologously expressed in Escherichia coli as a
46 KDa fusion protein and used for immunization of mice. The Ig response was studied by ELISA, whereas
the cytokine response was measured using a cytometric bead-based assay quantified by flow cytometry.
Result: Immunization with recombinant beta (β)-tubulin protein induced a beta-tubulin specific humoral
immune response of predominantly IgG2a isotype. Lethal challenge with T. evansi blood-form trypomastigotes
post-immunization elicited a robust anamnestic response. An abundance of IFN-γ further confirmed the Th-1
bias of the protective response. We also observed extended survival and better control of the challenge
infection in the immunized mice.
Conclusions: A robust anamnestic response following challenge including a Th-1 serum cytokine profile
coupled with increased survival is indicative of protective immunity in the immunized mice. These
observations suggest that β-tubulin of T. evansi is a viable antigenic target for development of a vaccine
against this important livestock pathogen.
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Trypanosoma evansi, a unicellular hemoflagellate, is the
causative agent of ‘surra’, a debilitating disease of a wide
range of livestock species in the tropics. This parasite is
transmitted mechanically among its wide range of suscep-
tible hosts by several species of hematophagous flies in
Asia, Africa, Latin America and parts of Europe [1–4].
The progression and outcome of infections varies widely
depending on the host species; fever, progressive anemia
or corneal opacity is typical in companion animals
whereas farm animals suffer from loss of condition, prod-
uctivity and draught efficiency, neurological abnormalities,
abortion or immunosuppression [5–8].
Management of surra is based chiefly on chemotherapy.
However, limited therapeutic options and the develop-
ment of drug-resistance have posed a major threat to our
abilities to contain the disease. The need for a safe and
cost-effective vaccine against surra [9] makes identifica-
tion of protective epitopes a priority. Though T. evansi
has an abundance of highly immunogenic glycoproteins
presented on its surface (variable surface glycoprotein,
VSG), the active and systematic variation of these surface
antigens during the course of an infection has limited the
prospects of targeting them for vaccine development [10].
Consequently, immunization strategies in surra have fo-
cused on various alternate, invariant, and often immuno-
logically subdominant epitopes [11–14].
Intracellular antigens can act as protective epitopes in
parasitic infections including malaria [15], schistosomo-
sis [16] and trypanosomosis [9, 10, 12] although the
underlying mechanisms have not been described. One
promising intracellular antigen of trypanosomes is beta
(β) tubulin which belongs to the large tubulin protein
family. Unlike in higher vertebrates and other inverte-
brates that possess orthologues of β tubulin with diverse
and dissimilar structural and functional attributes, try-
panosomes have a single isoform in the Trypanosomati-
dae [10]. This protein is an important structural
component of the flagellum and is critical for structural
stability and replication making it a promising thera-
peutic and vaccine target in protozoa [9]. Immunization
with native, recombinant or cDNA encoded trypanoso-
matid tubulin has shown varying levels of protection
against different African trypanosomes in experimental
surra [9, 10, 17].
Humoral immunity has long known to be important
in protection against African trypanosomes. Induction of
a rapid B-cell activation [18, 19] accompanied by a T
helper type (Th) 1 response with production of pro-
inflammatory cytokines is characteristic of successful im-
munological control of acute African trypanosomosis in
the host [20–23] . A fine balance between the pro-
inflammatory and anti-inflammatory cytokines that
effectively controls the parasitemia [24] and associatedanemia [25] in newly acquired infections are thought to
be responsible for trypanotolerance. In the present
study, we characterized the humoral antibody responses
and associated Th1-polarized serum cytokine profiles in
mice following immunization with recombinant T.
evansi β-tubulin that provided enhanced survival of mice
in the face of a lethal challenge infection.
Methods
Mice
Female Swiss albino mice (6–8 weeks) were procured
from the Laboratory Animal Research (LAR) Division,
Indian Veterinary Research Institute (IVRI), Izatnagar.
The mice were maintained under standard feeding and
rearing conditions at the lab animal housing facility of
the Division of Parasitology, IVRI, Izatnagar.
Recombinant expression-vector
The entire open reading frame (ORF) of T. evansi β-
tubulin (EU483116) was amplified by PCR from T.
evansi cDNA template with primers, F1X: 5′-AGAA
TTCCATGGGTGAGATTGTGTGCGT-3′ containing
Nco1 restriction site and R1X: 5′-TGAATTCTCGAGG-
TATTGCTCCTCCTCGTC-3′ containing the Xho1 re-
striction site. The purified PCR product was digested
with Nco1 and Xho1 and cloned into pQE TriSystem
plasmid vector (Qiagen, CA, USA) to give pQE-Te-β-
tubulin recombinant plasmid.
Expression of rTe-β-tubulin
Recombinant pQE-Te-β-tubulin construct was used for
expression of Te-β-tubulin in E. coli as per the manufac-
turer’s protocol (Qiagen, CA, USA). In short, 100 μl of
overnight culture of pQE-Te-β-tubulin transformed M15
strain E. coli was transferred into 50 ml of LB broth
(Thermo Scientific, MA, USA) containing 100 μg/ml
ampicillin and was allowed to grow in a shaking incuba-
tor at 37 °C until mid-log phase (~2 h) after which
isopropyl-beta-D-thiogalactopyranoside (IPTG) (Thermo
Scientific, MA, USA) was added at 1 mM final concen-
tration to induce expression. The culture was main-
tained for up to 6 h post induction. rTe-β-tubulin
produced in the E. coli cell lysate screened using SDS-
PAGE. The identity of the expressed protein was con-
firmed by western blot probed with anti-histidine (His)
tag antibody (Invitrogen, CA, USA). The His-tagged
rTe-β-tubulin present in the insoluble pellet was solubi-
lized under denaturing conditions with 8M urea, and
then purified using Ni-NTA agarose column (Qiagen,
CA, USA), renatured by dialysis (MWCO 10 K, Thermo
Scientific, MA, USA) against PBS, pH7.4, at 4 °C for
36 h and its purity determined by SDS-PAGE and stored
at −20 °C until use. The concentration of rTe-β-tubulin
was determined with modified Lowry protein assay kit
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Immunization and challenge
Female Swiss albino mice (6–8 weeks) were immunized
subcutaneously with 50 μg of rTe-β-tubulin in Freund’s
complete adjuvant (FCA) or with FCA alone as control.
Similar booster dosages were administered 21 days later,
but with incomplete Freund’s adjuvant (IFA). At 35 days
post primary immunization, all mice were challenged intra-
peritoneally with 103T. evansi blood form trypomastigotes.
Measurement of specific antibody response
The serum antibody response was studied by enzyme
linked immunosorbent assay (ELISA). A standard 96
well ELISA plate (Nunc, NY, USA) was coated for 1 h at
37 °C with the rTe-β-tubulin (5 μg/ml dissolved in
50 mM sodium carbonate coating buffer, pH 9.6)
followed by overnight blocking at 4 °C with 5 % bovine
serum albumin in PBS. After washing, 100 μl of heat
inactivated serum (56 °C for 30 min) from immunized
or naive mice was added at 1:50 dilution. After incubat-
ing for 2 h at 37 °C, sera samples were removed, the
wells washed and 100 μl of HRPase conjugated goat
anti-mouse IgG (Bangalore Genie, Karnataka, India) or
IgG2a (Santa Cruz, CA, USA) added at 1:5000 dilution
to the wells and incubated for 2 h at 37 °C. Washed
plates were developed for 15 mins at RT, using 100 μl/
well of OPD substrate (15 μg/ml in citrate phosphate
buffer, pH 5.0). The reaction was stopped by the
addition of 50 μl 2 M sulfuric acid and the plates were
read at OD492nm in a micro plate reader (Tecan, Manne-
dorf, Switzerland).
Measurement of serum cytokines
The concentration of Interleukin (IL)-4, IL-5, IL −10,
Interferon (IFN)- γ and Tumor Necrosis Factor (TNF)-α
were determined in the serum of mice every 24 h until
6 days post T. evansi challenge using the BD mouse
Th1/Th2 cytokine CBA Kit (BD Biosciences, CA, USA)
following the manufacturer’s protocol. Briefly, 50 μl of
diluted serum sample separated from blood collected
every 24 h post challenge, until 6 days was mixed with
50 μl of the mixed capture beads and 50 μl of the mouse
Th1/Th2 PE detection reagent. The tubes were incu-
bated at room temperature for 2 h in the dark, followed
by a wash. The samples were subsequently resuspended
in 300 μl of wash buffer before acquisition on the FACS
Calibur Flow Cytometer (BD Biosciences, CA, USA) and
analyzed using the FCAP Array Software (BD Biosci-
ences). Standard curves were generated for each cytokine
using the mixed bead standard provided with the kit and
were used to determine the concentration of each cyto-
kines in the serum samples. Serum IL-10 level wasdetermined using an ELISA based kit (Thermo Scientific,
MA, USA) following the manufacturer’s protocol.
Determination of parasitemia
The parasitemia in mice following T. evansi challenge
was monitored microscopically every 24 h from day 1
until 11 post infection using a standardized dilution of
blood obtained from tail bleeding. Counts are expressed
as trypomastigotes per 40× microscopic field and data
are presented as means for each time point.
Statistical analysis
Data are expressed as mean ± standard error of mean
(s.e.m) and are derived from at least triplicate observations
per sample per time-point. Results were analyzed by Stu-
dent t-test and differences were considered significant if
the p- value was ≤ 0.05.
Ethics statement
All animal experimentation was conducted in compli-
ance with the ethical considerations and guidelines
issued by the Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA) of
the Government of India and with the approval of the
Institutional Animal Ethics Committee (IAEC, IVRI)
regarding laboratory animals.
Results
Heterologous expression and purification of Te-β-tubulin
To generate rTe-β-tubulin, the amplified Te-β-tubulin
gene (Fig. 1a) from a cDNA template of T. evansi trypo-
mastigote stage was first cloned into the expression indu-
cible pQE-TriSystem vector. Escherichia coli transformed
with this construct expressed rTe-β-tubulin that was puri-
fied by affinity column chromatography (Fig. 1b). The
identity of expressed rTe-β-tubulin protein was confirmed
by Western blot (Fig. 1c).
Serum cytokine and antibody responses following
immunization
To determine cytokine responses following vaccination
and subsequent specific humoral immune response
mounted against rTe-β-tubulin, sera from mice inocu-
lated with rTe-β-tubulin (50 μg) in FCA or FCA alone
(control) were compared. At 24 h post inoculation, mice
inoculated with rTe-β-tubulin in FCA showed signifi-
cantly lower IL-4 and significantly higher TNF-α levels
in the serum compared to pre-immunization levels
(Fig. 2a). IL-4 or TNF-α levels in mice inoculated with
FCA alone did not differ significantly from the mice inoc-
ulated with rTe-β-tubulin in FCA (data not shown). At
14 days post inoculation, mice immunized with rTe-β-
tubulin had developed significantly higher titers of Te-β-
tubulin-specific IgG antibodies (1.8 fold higher OD492
Fig. 1 Heterologous expression of recombinant β-tubulin from T. evansi. a PCR amplification of T. evansi β-tubulin gene. b Induced heterologous
expression and purification of recombinant T. evansi β-tubulin protein (50 kDa) shown by SDS-PAGE. Protein molecular weight marker (Lane 1),
pre-induction Te-β-tubulin transgenic E. coli lysate (lane 2), induced Te-β-tubulin transgenic E.coli lysate collected 2, 4,or 6 h post-induction (lanes
3-5, respectively) and affinity-purified, renatured rTe-β-tubulin (lane 6). c Identity of the expressed rTe-β-tubulin confirmed by Western blot using
anti-His-tag antibody probing induced (4 h) Te-β-tubulin transgenic E. coli culture supernatant (lane 1), pre-induction (lane 2) or induced (4 h)
(lane 3) Te-β-tubulin transgenic E. coli lysate
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cific IgG2a titers in vaccinated mice were significantly
higher (7.7 fold higher OD492 readings) than FCA control
mice (Fig. 2b).
Serum cytokine and antibody responses following T.
evansi challenge
Mice challenged with a lethal dose of live blood stage T.
evansi 35 days post-immunization showed significantly
higher Te-β-tubulin specific (IgG) serum antibody titersa
*
*
Fig. 2 Trypanosoma evansi β-tubulin-specific immune response induced po
mice pre- and 24 h post-inoculation with FCA adjuvenated rTe-β-tubulin; aste
post-immunization mean levels for each cytokine. b Te-β-tubulin-specific IgG
rTe-β-tubulin or FCA control. Data presented as mean ± s.e.m. from at least 6 m
the mean OD492 values for serum IgG or IgG2a of FCA adjuvenated rTe-β-tubucompared to adjuvant-control or unimmunized mice at
4 days post-challenge (Fig. 3a). Mice inoculated with
rTe-β-tubulin in FCA and challenged with T. evansi
35 days post-immunization had dramatically different
kinetics of serum cytokine levels compared with mice
inoculated with FCA only (Figs. 3b-f ). Mice immunized
with rTe-β-tubulin demonstrated unchanging or slowly
dropping serum IL-4 and IL-5 concentrations following
challenge. Modest early (1–2 DPC) increases in the con-







st immunization with rTe-β-tubulin. a Serum levels of IL-4 and TNF-α in
risks indicate significant differences (p≤ 0.05) between the pre- and
and IgG2a antibody in mouse sera at 14 days post immunization with
ice/treatment; asterisks indicate significant differences (p≤ 0.05) between
lin vaccinated mice compared with FCA-only inoculated control mice
Fig. 3 Trypanosoma evansi β-tubulin specific recall response with Th1 polarization in lethal challenge of rTe-β-tubulin immunized mice. a Higher
rTe-β-tubulin specific (IgG) antibody titers in sera of mice immunized with rTe-β-tubulin and challenged with T. evansi blood stream forms; asterisk
indicates significant difference (p ≤ 0.05) between the mean OD492 value for serum IgG in the serum of rTe-β-tubulin immunized mice compared
with adjuvant and infection controls. b-f Kinetics of the serum levels of IL-4 (b), IL-5 (c), IFN-γ d and TNF-α (e) in rTe-β-tubulin or the adjuvant
control immunized mice post challenge with T. evansi blood stream forms. Data presented as mean ± s.e.m. from at least 6 mice/treatment
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with rTe-β-tubulin in FCA. In these same mice,
interferon-γ increased in concentration following chal-
lenge (peaking at 3 DPC) and then returned to lower
levels for the remainder of the challenge period. In con-
trast, all measured cytokines increased from their levels
at day of challenge until the end of the challenge period
in mice inoculated with FCA only.rTe-β-tubulin immunization enhanced survival following
T. evansi challenge
Mice immunized with rTe-β-tubulin exhibited a delayed
appearance, as well as lower numbers, of T. evansi try-
pomastigotes in blood following challenge (Fig. 4a). All
mice in the FCA only control group died by day 6 post
challenge whereas all mice immunized with rTe-β-tubu-
lin in FCA survived until at least day 10 post challenge.
Fig. 4 Mice immunized with rTe-β-tubulin are better protected from
a lethal challenge with T. evansi. The rTe-β-tubulin immunized mice
demonstrated lower parasitemia (a) and prolonged survival (b)
following a virulent T. evansi challenge compared with similarly
challenged adjuvant only controls. Daily counts of bloodstream
trypomastigotes represent means ± s.e.m. from at least 10 mice
per treatment
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cumbed to infection by 28 days post challenge (Fig. 4b).
Discussion
Surra is an insidious disease complex caused by the uni-
cellular, flagellated protozoan T. evansi that leads to the
development of severe and often fatal anemia. The infec-
tion is prevalent in a wide range of domestic and wild
animal species across the tropical and semitropical re-
gions of Eurasia and Africa [8]. Although management
of the disease by chemotherapy is feasible, its successful
application is limited by the low sensitivity of conven-
tional microscopy and serological tools that prevent the
timely identification of chronic infections and carrier
animals. The spread of the infection in susceptible ani-
mals often remains unchecked impacting the health and
productivity of livestock in the tropics. The ability of T.
evansi to vary its immuno-dominant major surface anti-
gen to escape host immune responses limits the pros-
pects of developing a conventional vaccine against T.
evansi targeting epitopes typically exposed on the
plasma membrane of the parasite [10]. Consequently,
evaluation of internal antigens of T. evansi (e.g.molecules not typically exposed on the cell surface) for
their ability to induce protective immune responses has
become necessary [10, 17].
There have been multiple attempts at developing na-
tive or recombinant protein based vaccines against vari-
ous protozoal infections but often with limited success
compared vaccines based on whole organisms that better
reflect the complexity of the target pathogen [26, 27].
Protective immunization against African trypanosomosis
has been particularly challenging owing to the sequential
expression of variable surface antigen molecules by the
parasite that efficiently subverts the humoral immune
responses [14, 28]. However, induction of protective
immunity to various levels has been achieved by targeting
invariable antigens on African trypanosomes; mice vacci-
nated with native tubulin purified from T. b. brucei were
protected from T. b. brucei, T. congolense or T. b. rhode-
siense infections [9]. Likewise, immunization with the
microtubule associated protein (MAP) p52, GAPDH and
MAP p15 protected mice from T. brucei challenge [29].
Recombinant protein [10, 12] or DNA [17] based vaccines
targeting the tubulin of various African trypanosomes
have also provided partial protection.
Production of IgG2 antibodies and the activity of cyto-
toxic T cells are characteristics of Th1 immune response
in mice, whereas a predominance of IgM, IgG1, IgA and
IgE class antibodies represent Th2 response. In general,
vaccines adjuvenated with FCA and delivered subcutane-
ously generate a Th1 rather than Th2 type immune re-
sponse [30]. We observed significantly higher titers of T.
evansi β tubulin specific IgG antibody, specifically of
IgG2a isotype, with higher concentrations of TNF-α and
lower concentrations of IL-4 in the serum following rTe-
β-tubulin immunization in mice. Immunized mice dem-
onstrated a progressive drop in serum IL-5 and IL-10
concentrations following challenge. Serum IFN-γ con-
centration increased in rTe-β-tubulin-immunized mice
but dropped after 3 days post challenge. Such serum
cytokine profiles suggest a strongly Th1 polarized im-
mune response. Mice immunized with rTe-β-tubulin
also showed falling TNF-α serum concentrations follow-
ing a brief rise immediately post challenge, suggesting
better protection and reduced pathological changes.
These results suggest that rTe-β-tubulin immunization
promotes a Th1-biased recall response following T.
evansi challenge. Such a Th1 polarized response has
been shown to be pivotal for protection against T. evansi
infections [20–23, 31] as was demonstrated by the
longer survival of vaccinates in the present study.
Although the role of adaptive immunity in protection
against extracellular pathogens such as trypanosomes
are well recognized [32, 33], the independent contribu-
tions of the cell-mediated or humoral immune mecha-
nisms are less well understood. Profiles of induced
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of immune responses mounted by the host against a
pathogen and may aid in predicting the outcome of
infection. Although the levels of various cytokines have
served as reliable indicators of the impact of a pathogen
on a host, studies [34–36] have shown repeatedly that
attempting to predict the outcome of an infection based
on a single cytokine response is unlikely to be successful.
For example, IFN-γ, an important cytokine of the Th1
subset, activates and stimulates the macrophages to
produce IL-12 that not only helps in differentiation of
Th1 cells, but also inhibits the expansion of Th2 type
T-cell population. IFN-γ also induces class switching to
IgG2a [37] and is a hallmark of humoral immunity to
trypanosomosis in various natural and experimental
hosts [20–23, 31]. Mice immunized with rTe-β-tubulin
showed higher serum levels of IFNγ following T. evansi
challenge compared to mice immunized with the adju-
vant alone. In the present study, elevated IFN-γ levels
may have contributed to the better control of T. evansi
parasitemia observed in the immunized compared to
sham-immunized mice. However, enhanced production
of IFN-γ has also been correlated with early mortality in
mice infected with T. congolense or T. brucei [38, 39],
primarily owing to the systemic inflammatory response
syndrome (SIRS). This was further substantiated by the
observation that anti-IFNγ antibodies could prevent early
mortality in these infections [40].
The ability of elevated IFNγ levels following virulent
challenge with T. evansi to both aid control of parasit-
emia and simultaneously exacerbate damage to the host
may be explained by the varied roles that IFN-γ plays in
the host. Barkhuizen et al. [41] showed that IFN-γ plays
a central role in resistance against trypanosomosis by
inducing macrophages to generate trypanocidal mole-
cules such as reactive oxygen intermediates, reactive ni-
trogen intermediates or TNF-α. Although TNF-α is vital
for resistance against trypanosomosis [31], increasing
TNF-α levels indicate a failing immune system and an
uncontained infection [42–44]. Additionally, it has been
challenging to determine if an individual cytokine
response is a consequence of an infection or exacerbates
one. For example, a surge in IL-10 in serum often fol-
lows release of pro-inflammatory cytokines such IFN-γ
during an infection; in such cases the surge in IL-10 pro-
duction is a consequence of inflammation rather than a
contributor to it [45]. The cytokines IL-4, IL-5 and IL-10
are thought to balance the pro-inflammatory milieu gen-
erated in an infection to keep the host tissue safe from
its own inflammatory immune responses. In the pro-
tected mice, we observed a spike in serum IFN-γ levels
concurrently with lower IL-4 and IL-5 levels immedi-
ately after challenge. This IFN-γ surge is followed by a
sudden decrease, most likely associated with a control ofthe infection, as indicated by a corresponding drop of
IL-10 and TNF-α concentration in the serum. Although
it may be difficult to predict the outcome of an infection
from the levels and patterns of individual serum cyto-
kine responses, deducing overall cytokine profiles by
measuring multiple, interacting cytokines helps in pre-
dicting the course of the infection. This knowledge
might also help to define a desirable protective cytokine
profile indicative of successful vaccination.
Conclusions
Mice immunized with rTe-β-tubulin in this study
showed a predominant Th1 polarization in the elicited
immune response as evidenced by both the cytokine
profile and the IgG2a isotype of circulating anti-Te-β-
tubulin antibodies generated in immunized mice. In-
creased resistance to trypanosomosis in mice may be
correlated with higher serum level of the parasite spe-
cific IgG2a antibodies; the elevated serum titers of anti-
tubulin IgG2a class antibodies post-immunization likely
contributed to our observed protection of mice from the
lethal challenge. This study reasserts the potential of
prima facie concealed antigens in eliciting protective
humoral immune responses against pathogens; such
cryptic antigens may be crucial resources in the fight
against complex eukaryotic pathogens and their compli-
cated biologies.
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